Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119686 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL30062876 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29398457 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL178739 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118173 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL23722984 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119459 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119456 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29709621 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL31437097 | 0.97 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | ZHEJIANG PEPTITES BIOTECH CO., LTD. (CN) | 2025-12-23 | — | — | US | claimed |
| US-20240116980-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | ZHEJIANG PEPTITES BIOTECH CO., LTD (CN) | 2024-04-11 | — | — | US | claimed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | claimed |
| CN-112585153-B | Compound or salt thereof, and preparation method and application thereof | 浙江湃肽生物有限公司 | 2023-10-13 | — | — | CN | claimed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | ZHEJIANG PEPTITES BIOTECH CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240116980-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | ZHEJIANG PEPTITES BIOTECH CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | disclosed |
| CN-112585153-B | Compound or salt thereof, and preparation method and application thereof | 浙江湃肽生物有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230041996-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOUND AND APPLICATION THEREOF | BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4091623-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOUND AND APPLICATION THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | TP53, MDM2, MDM4 | MDM4 3/4885TP53 1/4885CASP3 2615/4885 |
| US-20240116980-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | SEM1, REN, SETDB1 | MDM4 4729/4885TP53 4748/4885CASP3 4261/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885CASP3 2306/4885 |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | SEM1, REN, SETDB1 | MDM4 4729/4885TP53 4748/4885CASP3 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.